Shannon Heaning, Content Associate

Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.

Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.

Dermatology Times and Physicians' Education Resource will host DermNexus Congress, a two-day CME program for nurse practitioners and physician assistants, November 20–21 in Scottsdale, Arizona.

James Caleb Runyon, MSN, NP-C, shared lessons on building an advocacy initiative, developing partnerships, and balancing advocacy with clinical practice.

Amit Om, MD, discussed Mohs surgery, its high cure rates, patient education, and the importance of collaboration across dermatology care teams.

An HS toolbox with wound care, symptom relief, and personal care supplies can help patients stay prepared for unexpected flares.

The inaugural workshop explored skin cancer care from prevention and diagnosis through systemic therapy, radiation, and multidisciplinary management.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

The expanded indication makes Ameluz with RhodoLED the first FDA-approved photodynamic therapy for the treatment of a skin cancer.

Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.

The final session of the Cutaneous Oncology Workshop explored advances in systemic therapy, management of immunotherapy-related skin reactions, and the role of radiation.

Attendees put technique into practice during an interactive suturing session led by Tristan Hasbargen, PA-C, using individual kits and real-world clinical examples.

At the Cutaneous Oncology Workshop, faculty explored lesion recognition, surgical decision-making, risk stratification, and the evolving role of molecular testing.

Faculty at the Dermatology Times Cutaneous Oncology Workshop addressed real-world questions on mole mapping, biopsy decisions, oral photoprotection, and actinic keratosis treatment.

In the morning session, Experts highlighted evolving photoprotection strategies, field-directed treatment of actinic keratoses, hereditary cancer risk, and practical dermoscopy pearls for APPs.

Dermatology Times kicks off its first Cutaneous Oncology Workshop, bringing APPs and experts together for practical skin cancer education.

Isotretinoin Effect on Adult Height in Danish Cohort Study

Twenty-five years after September 11, Dermatology Times reflects on the burn injuries, skin conditions, and clinicians who cared for survivors.

Dietary modification may improve disease activity and quality of life in some patients with chronic idiopathic urticaria.

Phase 2 SkinJect data support the 200-µg dose and inform Medicus’ FDA-authorized registrational program in Gorlin syndrome.

A 3-patient case series explored photothermal biomodulated PRP with laser and LED therapy for acne-related erythema, hyperpigmentation, and scarring.

Dietary changes may help some patients with chronic urticaria, but evidence does not yet support a standardized diet.

James Caleb Runyon, MSN, APRN, FNP-C, discussed how his Closer Look Project trains personal care professionals to recognize signs of skin cancer.

Advanced practice providers will gather September 12 for a full-day program covering skin cancer prevention, diagnosis, staging, treatment, and procedural skills.

Robert R. Redfield, MD, will help guide development of GX-03 as Turn Therapeutics advances its phase 2 atopic dermatitis program.

FDA granted QRX003 RPD designation for PSS, adding to its Netherton syndrome designation as Quoin prepares for a phase 2 study.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Stay ahead with a weekly roundup of the biggest practice management, AI, policy, business, and professional development updates in dermatology.

A teen with persistent atopic dermatitis has tried multiple topicals but wants to avoid injectables. Work through the case and decide whether you would try another topical or escalate treatment.

AbbVie completed its $10.9 billion Apogee acquisition, adding IL-13 antibody zumilokibart and other inflammatory disease assets.